Send me real-time posts from this site at my email
Wild Tiger Trading

Trading List: Favorites & Trade ideas - Dec. 15 Update

Current favorites:


$AMRN - Amarin - Removed from last update as the court loss to generic drug makers has us looking elsewhere for better opportunities.


$AUPH - Aurinia Pharma - Has previously completed a rolling submission of a New Drug Application to the United States FDA for voclosporin as a potential treatment for lupus nephritis. The drug candidate has the potential to become the first FDA-approved therapy for treating lupus nephritis.

Cowen calls Aurinia a best idea for 2021 into FDA action date: Aurinia Pharmaceuticals is positioned for a "meaningful inflection" into the January 22 FDA action date for voclosporin in lupus nephritis, Cowen analyst Ken Cacciatore tells investors in a research note. Citing voclosporin's efficacy and safety, combined with clinician enthusiasm and an unmet clinical need, the analyst has "strong conviction" that voclosporin should be "rapidly incorporated" into the standard of care and has $1B-PLUS sales potential. He calls Aurinia a best for 2021 and recommends adding to positions at current levels. Cacciatore keeps an Outperform rating on the shares with a $30 price target.

Our Take: 
 We expect approval and see this as having nice potential. Buy the stock outright or sell some naked puts or both!


$BFYT - Benefytt Tech - Removed from the list as it was BOUGHT OUT!  Benefytt Technologies to be acquired by MDP Funds for $31.00 per share. This was just over a 50% premium for our readers!

Our Take:  Congrats to our readers who got in on this.


$EPZM - Epizyme - Back on October 5th after Bristol-Myers ($BMY) bought out MyoKardia ($MYOK) the Citi analyst Mohit Bansal mentioned Epizyme. 

Bansal highlights Epizyme as a potential target.
Bansal adds that Epizyme is a top pick given the view that the Street is underestimating the revenue potential for its lymphoma drug Tazverik. However, for M&A to happen, Bansal believes the company will likely have to show a couple of good quarters of sales after the drug's launch. Bansal sees an M&A valuation of Epizyme at $45-$55 per share, the analyst added.

Nov 9 - Epizyme price target lowered to $18 from $33 at Barclays. Barclays analyst Peter Lawson lowered the firm's price target on Epizyme to $18 from $33 and keeps an Overweight rating on the shares after tazemetostat sales missed Q3 estimates.

Our Take:  EPZM has some good potential with Tazverik, but does have some risk with that and tazemetostat making estimates or not. We see the risk/reward being positive for traders. With the volatility in this name, it is good for trading options around your positions.


$EXEL - Exelixis - Another biotech with high volatility for trading. Unlike most biotechs this one is making money.

Back in Sept. Piper Sandler analyst Edward Tenthoff kept his Overweight rating and $30 price target on Exelixis after the company disclosed in an ASCO abstract that CABOMETYX combination with checkpoint inhibitors has now been active in multiple solid tumors. The analyst continues to forecast product sales of $776M in 2020, noting that the expected presentation of mCRPC data could form the basis for accelerated approval in 2021, with label expansions re-accelerating CABO sales to $918M in 2021.

Our Take:  Exelixis is a high potential biotech that makes money and is working on label expansions. Nice for trading purposes as well. Possible buyout candidate.


$HZNP - Horizon Therapeutics - This one has tripled for our readers since the March lows! Near all-time highs and keeps growing earnings momentum. A good longer term buy and trading stock in the biotech/drug space. Recently mentioned favorably by the following analysts.

11/03 Horizon Therapeutics price target raised to $110 from $105 at BMO Capital

BMO Capital analyst Gary Nachman raised the firm's price target on Horizon Therapeutics to $110 from $105 and keeps an Outperform rating on the shares. The company's Q3 was "very strong" and its launch of Tepezza continued "to impress", boosting expectations in spite of the COVID-19 impact, the analyst tells investors in a research note. Nachman adds that both Tepezza and Krystexxa contributed to a "solid" guidance raise for 2020.

11/03 Horizon Therapeutics price target raised to $116 from $112 at Citi

Citi analyst Navann Ty raised the firm's price target on Horizon Therapeutics to $116 from $112 and keeps a Buy rating on the shares following the company's Q3 results. The analyst expects "consistent execution" of the Tepezza launch and believes fiscal 2021 sales consensus for the drug is still beatable.

Our Take:  A big winner this year with earnings continuing to grow and analysts raising their price targets. With this one it is a longer-term buy and hold like stock with some dips and peaks to be bought/sold. Selling covered calls here for cash is also a good bet at times.


$IMMU - Immunomedics - Another HUGE WINNER for our readers! This one more than doubled a few months back when Gilead ($GILD) bought them out for $88/SHARE! Before this buyout we mentioned that there metastatic triple-negative breast cancer would be approved by the FDA and it did. Shortly after that Gilead stepped in to take them out.

Our Take:  Congrats to our readers who woke up one morning to see the news and the price double overnight!


$IOVA - Iovance - Been a very volatile biotech stock lately. Mentioned periodically as a takeover/buyout target. Mentioned positively by a few analysts.

11/09 Iovance data bode well for future combo readouts, says Piper Sandler

Today's initial data for LN-145 plus pembrolizumab in advanced, recurrent, or metastatic head and neck squamous cell carcinoma "provided a modest update that is very much consistent with the abstract," Piper Sandler analyst Joseph Catanzaro tells investors in a research note. The early data continue to show significant outperformance over single-agent checkpoint at overall response rate in this population, says the analyst. He thinks these early data bode well for future PD-1 combination readouts in non-small-cell lung carcinoma, melanoma and cervical cancer. Catanzaro keeps an Overweight rating on Iovance with a $45 price target.

11/06 Iovance Biotherapeutics price target raised to $43 from $36 at Barclays

11/06 IOVA Barclays analyst Peter Lawson raised the firm's price target on Iovance Biotherapeutics to $43 from $36 and keeps an Overweight rating on the shares. The Biologics License Application for melanoma is on track for 2021, Lawson tells investors in a research note.

11/06 Iovance Biotherapeutics price target raised to $45 from $35 at Piper Sandler

Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Iovance Biotherapeutics to $45 from $35 and keeps an Overweight rating on the shares. The potential registrational path for LN-145 in Non-small-cell lung carcinoma is starting to come into the picture, Catanzaro tells investors in a research note.

Our Take:  This has had some volatility due to a manufacturing issue back in early October, but has almost doubled since! Iovance has some big potential. Also, with the volatility the options in this one offer some good premiums. Selling naked puts to buy the stock or doing a few buy/writes maybe a good bet in addition to buy and hold it.


$KPTI - Karyopharm - A speculative and volatile biotech name. They do have a FDA approved product (Xpovio) and are currently seeking approval for other indications/uses.

12/11 Karyopharm's NCCN inclusion should benefit uptake of Xpovio, says RBC Capital

After Karyopharm Therapeutics announced that the National Comprehensive Cancer Network, or "NCCN," has added three different Xpovio combination regimens to its Clinical Practice Guidelines in Oncology for previously treated multiple myeloma, or MM. RBC Capital analyst Brian Abrahams noted that this inclusion immediately enables payer reimbursement for Xpovio in these combinations in the earlier-line MM setting. Karyopharm is still waiting for FDA approval in the earlier-line indications and he continues to hear that access has been "the dominant barrier" to off label prescribing of Xpovio in this setting, said Abrahams. The analyst, who argues that any early signals of uptake ahead of an anticipated March 2021 approval and formal launch "could serve as an important early indicator of the agent's long-term potential," keeps an Outperform rating on Karyopharm shares.

Our Take:  The risk reward here is becoming more favorable. The stock does offer some trading opportunities with the volatility of it's stock price. We think anything under $15 is a good buy price.


$SGMO - Sangamo - Gene Editing company who already had big pharma partnerships.

Our Take:  A good buy and hold in a rapidly growing field with some volatility for trading around a core position. Recent test results with partner Pfizer ($PFE) are going well. Large pipeline and future potential.


$TGTX - TG Therapeutics - One of our BEST performing picks. Our TOP PICK! This one has multiple drugs in Phase 3 trials and some test data on these drugs has been outstanding. This stock jumped 40% in one day back on Thursday Dec. 10 on very strong MS drug trial results! The stock had more than tripled in the last 9 months.

12/10 TG Therapeutics price target raised to $61 from $38 at H.C. Wainwright

H.C. Wainwright analyst Edward White raised the firm's price target on TG Therapeutics to $61 from $38 and keeps a Buy rating on the shares after the company announced positive top-line results from the Phase 3 ULTIMATE I and II trials. Both studies met their primary endpoint, demonstrating a statistically significant reduction in annualized relapse rate following 96 weeks of therapy, White tells investors in a research note. The analyst does not expect safety to be an issue in the Phase 3 studies.

12/10 TG Therapeutics price target raised to $70 from $65 at Evercore ISI

Evercore ISI analyst Joshua Schimmer raised the firm's price target on TG Therapeutics to $70 from $65 and keeps an Outperform rating on the shares after the company announced that two Phase 3 studies evaluating ublituximab compared to teriflunomide in patients with relapsing forms of multiple sclerosis both met their primary endpoint. The data give TG Therapeutics "a clear differentiating message" of offering strong efficacy and a shorter infusion time compared to Ocrevus, the analyst said.

Our Take:  A huge winner with much potential still ahead as they have multiple drugs in Phase 3 trials with good results so far. This is a buy and hold now, but does have good volatility for trading around a position as well. Two years ago we had this at $6 bucks and now it is 7 times higher and still going/growing.

NOTE:  They just announced a Secondary offering and it was oversubscribed and the buyers were given no discount! This is a very good positive.  See the story here > TGTX offering priced at $43.50


$TGTX, TG Therapeutics, Inc. / H1

If your thinking longer-term/income:

$T - AT&T is worth a look - high dividend yield. (Approx. 7%).


Tech Pick:

$CRWD - CrowdStrike - Analysts continuing to raise their price targets!

12/04 Crowdstrike price target raised to $150 from $125 at Credit Suisse

Credit Suisse analyst Brad Zelnick raised the firm's price target on Crowdstrike to $150 from $125 and keeps a Neutral rating on the shares. CrowdsStrike reported strong results, with net new ARR +49% y/y, Zelnick tells investors in a research note. The analyst continues to view Crowdstrike as a secular winner in its space, leveraging cloud scale data and a single agent architecture to drive endpoint consolidation as well as cloud workload protection.

12/03 Crowdstrike price target raised to $190 from $164 at Oppenheimer

Oppenheimer analyst Shaul Eyal raised the firm's price target on Crowdstrike to $190 from $164 and keeps an Outperform rating on the shares. The analyst notes that Crowdstrike's Q3 outperformance showed comfortable upside to Street's expectations on revenue, margins/EPS, CFO, and ARR. Fiscal year 2021 guidance was again raised, this time by $39.6M at the midpoint to 78% year-over-year growth.

Our Take:  This is a cyber security play and has recently taken off in share price. That is the only caution we have in this name, it has already had a good run up and may get overvalued at times. Buy the dips and sell the peaks on this one along with buy and hold as it is a tech growth name in a currently very favorable field.


Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.

.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue